ErbB/HER Receptor Antagonists Market Explored by La Merie in New In-demand Study Now Available at MarketPublishers.com

25 Jul 2013 • by Natalie Aster

LONDON – Targeted monoclonal antibody-based therapy for EGFR-positive and HER2-positive tumours has become an example of how effective personalized medicine can be. The success of small molecule ErbB/HER receptor tyrosine kinase inhibitors and EGFR- and HER2-targeted antibody therapy has instigated the discovery and elaboration of efficacy improved versions as well as of ErbB dual or multitargeted cancer therapies.

New in-demand report “Competitor Analysis ErbB / Her Receptor Antagonists” worked out by La Merie provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (HER), ErbB3 (HER) and ErbB4 (HER4) receptor targeting molecules for treatment of cancer.

The study includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/HER family. Furthermore, the research provides a listing of company-specific R&D pipelines of ErbB/HER receptor targeting molecular entities. Competitor projects disclose information on: drug codes; target/mechanism of action; class of compound; company; product category; indication; and R&D stage.

Report Details:

Competitor Analysis ErbB/Her Receptor Antagonists
Published: July, 2013
Pages: 168
Price: US$ 853.00

Other Publications and Databases by La Merie Include:

More new studies by the publisher can be found at La Merie page.

Contacts

MarketPublishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com